• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

COA Releases Statement on Prescription Drug Pricing Reduction Act

Article

On behalf of the Community Oncology Alliance (COA), Ted Okon, executive director of COA, has released a statement regarding the Prescription Drug Pricing Reduction Act.

On behalf of the Community Oncology Alliance (COA), Ted Okon, executive director of COA, has released a statement regarding the Prescription Drug Pricing Reduction Act. While COA supports certain provisions in the package, including encouraging a healthy and competitive biosimilars market, transparency around pharmacy benefit managers, and changes to grandfathered site-neutral payments for hospitals, there are some provisions COA is opposed to. For example: the proposal to include support from patient assistance programs in the calculation of Average Sales Price, which is the basis for Medicare Part B drug reimbursement.

According to Okon, the provision would lead to drug manufacturers to reduce or eliminate programs. Read the full press release.

Related Videos
Pregnant Patient | image credit: pressmaster - stock.adobe.com
Dr Julie Patterson, National Pharmaceutical Council
Diana Isaacs, PharmD
Beau Raymond, MD
Robert Zimmerman, MD
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Beau Raymond, MD
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Kimberly Westrich, MA
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.